Methods of Treating Psoriasis Using IL-17 Antibody
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application PCT/EP2011/067522, filed Oct 7, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,551,554 | Methods of Treating Chronic Inflammatory Disease with Secukinumab In force · Medium confidence | Novartis Pharma AG | In force | Medium confidence | ||
| US 12,594,331 | Methods of Treating Psoriasis with Secukinumab In force · Medium confidence | Novartis Pharma AG | In force | Medium confidence | ||
| US 12,594,332 | Methods of Treating Psoriasis with Secukinumab In force · Medium confidence | Novartis Pharma AG | In force | Medium confidence | ||
| US 10,583,190 | Methods of Treating Psoriasis Using IL-17 Antibodies In force · Medium confidence | Novartis Pharma AG | In force | Medium confidence | ||
| US 11,534,490 | Methods of Treating Psoriasis Using IL-17 Antagonists In force · Medium confidence | Novartis Pharma AG | In force | Medium confidence | ||
| US 9,717,791 | Methods of Treating Psoriasis Using IL-17 Antibody In force · High confidence | Novartis Pharma AG | In force | High confidence | ||
| Application 18/061,227 | Methods of Treating Psoriasis Using IL-17 Antagonists Pending Not granted | Novartis Pharma AG | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Novartis Pharma AG.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.